The first clinically oriented handbook on using antipsychotic levels for managing adherence and optimizing treatment effectiveness. Covers concepts of response threshold, the point of futility and correlations between antipsychotic dosages and trough levels. For all clinicians working with psychiatric patients receiving antipsychotic therapy.
The first clinically oriented handbook on using antipsychotic levels for managing adherence and optimizing treatment effectiveness. Covers concepts of response threshold, the point of futility and correlations between antipsychotic dosages and trough levels. For all clinicians working with psychiatric patients receiving antipsychotic therapy.
Jonathan M. Meyer is a Clinical Professor of Psychiatry at the University of California, San Diego, and a Psychopharmacology Consultant to the California Department of State Hospitals.
Inhaltsangabe
Preface Introduction 1. Sampling times for oral and long-acting injectable agents 2. The therapeutic threshold and the point of futility 3. Level interpretation including laboratory reporting issues, responding to high plasma levels, special situations (hepatic dysfunction, renal dysfunction and hemodialysis, bariatric surgery) 4. Tracking oral antipsychotic adherence 5. What is an adequate antipsychotic trial - using plasma levels to optimize psychiatric response and tolerability 6. Important concepts about first generation antipsychotics 7. Haloperidol and haloperidol decanoate 8. Fluphenazine and fluphenazine decanoate 9. Perphenazine and perphenazine decanoate 10. Zuclopenthixol and zuclopenthixol decanoate flupenthixol and flupenthixol decanoate 11. Chlorpromazine, loxapine, thiothixene, trifluoperazine 12. Important concepts about second generation antipsychotics 13. Clozapine 14. Risperidone oral and long-acting injectable, paliperidone oral and long-acting injectable 15. Olanzapine and olanzapine pamoate 16. Aripiprazole, aripiprazole monohydrate and aripiprazole lauroxil 17. Amisulpride, asenapine, lurasidone, brexpiprazole, cariprazine Appendix Therapeutic threshold, point of futility, AGNP/ASCP laboratory alert level, and average oral concentration-dose relationships.
Preface Introduction 1. Sampling times for oral and long-acting injectable agents 2. The therapeutic threshold and the point of futility 3. Level interpretation including laboratory reporting issues, responding to high plasma levels, special situations (hepatic dysfunction, renal dysfunction and hemodialysis, bariatric surgery) 4. Tracking oral antipsychotic adherence 5. What is an adequate antipsychotic trial - using plasma levels to optimize psychiatric response and tolerability 6. Important concepts about first generation antipsychotics 7. Haloperidol and haloperidol decanoate 8. Fluphenazine and fluphenazine decanoate 9. Perphenazine and perphenazine decanoate 10. Zuclopenthixol and zuclopenthixol decanoate flupenthixol and flupenthixol decanoate 11. Chlorpromazine, loxapine, thiothixene, trifluoperazine 12. Important concepts about second generation antipsychotics 13. Clozapine 14. Risperidone oral and long-acting injectable, paliperidone oral and long-acting injectable 15. Olanzapine and olanzapine pamoate 16. Aripiprazole, aripiprazole monohydrate and aripiprazole lauroxil 17. Amisulpride, asenapine, lurasidone, brexpiprazole, cariprazine Appendix Therapeutic threshold, point of futility, AGNP/ASCP laboratory alert level, and average oral concentration-dose relationships.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
